González D, Vinent G, Rodríguez MC, Rodríguez M

Language: Spanish
References: 15
Page: 47-50
PDF size: 101.54 Kb.

ABSTRACT

The gangliosides are glycosphingolipids that are distributed in the organism in different forms. The presence of the ganglioside N-Glycolil GM3 (NGcGM3) has been described in human tumoral cells, that is why it has became an attractive target for the specific antitumoral therapy. This molecule is the main component of the vaccine candidate for breast cancer in clinical trials phase. Lactose acceptor is a key intermediate to obtain this ganglioside by chemical synthesis, the protection of the positions 3´,4´ of lactose with an isopropiliden group is necessary in the synthesis of lactose acceptors that will be used to form part of oligosaccharides and glycoconjugates. This work is focused in the reaction to obtain 3',4'-lactose-isopropiliden, an intermediate in lactose acceptor synthesis. The reaction conditions were studied and the best results were found working at +1 level of temperature and -1 level of time reaction. The reaction was made in a 5 L reactor and the results were reproducible. The thin layer semi-quantitative chromatography was chosen to quantify the amount of the isomers 3´,4´ and 4',6'-lactose isopropiliden obtained in the reaction.

REFERENCES

1. Fraser-Reid BO, Taksuta K, Thieme J. Glycoscience. Chemistry and Chemical Biology. Berlín: Springer; 2001.

2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer inmunoediting. Annual Review of Immunology 2004;22:329-60.

3. Oliva JP. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using 14f7 monoclonal antibody labeled with 99mTc. Breast cancer Research and Treatment 2006;92(2):115-21.

4. De León J, Fernández A, Clavell M, López A, Labrada M, Bebelagua Y, et al. La variante N-glicolilada del gangliósido GM3 en la biología de los tumores: un blanco atractivo para la inmunoterapia del cáncer. Biotecnología Aplicada 2008;25(2):161-5.

5. Mulens V, Marinello P, Carr A, Mazorra Z, Fernández LE. Gangliósidos en la Biología e Inmunoterapia del Cáncer: la Experiencia Cubana. Cancerología 2009;13(4):155-67.

6. Blanco R, Quintana Y, Blanco D, Cedeño M, Rengifo E, Frómeta M, et al. Tissue Reactivity of the 14F7 Mab Raised against NGlycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin. Journal of Biomarkers 2013. (2013):1-9. Consultado en: doi.org/10.1155/2013/602417

7. Blanco R, Rengifo ChE, Cedeño M, Frómeta M, Rengifo E, Carr A. Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Pathology Research International 2012; 2012:1-12. Disponible en: http://www.hindawi.com/ journals/pri/2012/235418/

8. Marquina G, Waki H, Fernández LE, Carr A, Valiente O. Gangliosides expressed in human breast cancer. Cancer Research 1996;56(22):5165-71.

9. Carr A, Mulet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19(3):241-7.

10. Baer HH, Abbas SA. Synthesis of O-α-L-fucopyranosyl-(1-3)- O-β-D-galactopyranosyl-(1-4)-D-glucose(3´-O-α-Lfucopyranosyllactose), and animprovedroutetoits β-(1´-3´)- linkedisomer. Carbohydrate Research 1980;84(2):53-60.

11. Duclos RI. The total synthesis of ganglioside GM3. Carbohydrate Research 2000;328(4):489-507.

12. Turner C. Modern Extraction Tecnics. Washington: American Chemical Society; 2006.

13. Levenspiel O. Chemical Reaction Engineering. New York: John Wiley Sons; 1999.

14. McCabe WL, Smith CJ. Operaciones Básicas en Ingeniería Química. New York: McGraw Hill; 2002.

15. Hicks RW, Morton JR, Fenic JG. How to design agitators for desired process response. Chemical Engineering 1976;83(7):102-10.